Cargando…
PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243109/ http://dx.doi.org/10.1186/bcr3735 |
| _version_ | 1782346061200752640 |
|---|---|
| author | Millican-Slater, R Dodwell, D Horgan, K Mcmahon, M Dall, B Sharma, N |
| author_facet | Millican-Slater, R Dodwell, D Horgan, K Mcmahon, M Dall, B Sharma, N |
| author_sort | Millican-Slater, R |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4243109 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42431092014-11-26 PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab? Millican-Slater, R Dodwell, D Horgan, K Mcmahon, M Dall, B Sharma, N Breast Cancer Res Poster Presentation BioMed Central 2014 2014-11-03 /pmc/articles/PMC4243109/ http://dx.doi.org/10.1186/bcr3735 Text en Copyright © 2014 Millican-Slater et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Millican-Slater, R Dodwell, D Horgan, K Mcmahon, M Dall, B Sharma, N PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab? |
| title | PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab? |
| title_full | PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab? |
| title_fullStr | PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab? |
| title_full_unstemmed | PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab? |
| title_short | PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab? |
| title_sort | pb.40. what happens to the ductal carcinoma in situ in her2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab? |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243109/ http://dx.doi.org/10.1186/bcr3735 |
| work_keys_str_mv | AT millicanslaterr pb40whathappenstotheductalcarcinomainsituinher2positivecancerstreatedwithneoadjuvantchemotherapyandtrastuzumab AT dodwelld pb40whathappenstotheductalcarcinomainsituinher2positivecancerstreatedwithneoadjuvantchemotherapyandtrastuzumab AT horgank pb40whathappenstotheductalcarcinomainsituinher2positivecancerstreatedwithneoadjuvantchemotherapyandtrastuzumab AT mcmahonm pb40whathappenstotheductalcarcinomainsituinher2positivecancerstreatedwithneoadjuvantchemotherapyandtrastuzumab AT dallb pb40whathappenstotheductalcarcinomainsituinher2positivecancerstreatedwithneoadjuvantchemotherapyandtrastuzumab AT sharman pb40whathappenstotheductalcarcinomainsituinher2positivecancerstreatedwithneoadjuvantchemotherapyandtrastuzumab |